RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Primary Biliary Cholangitis: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Depressive Symptoms, Sleep Quality, and Anhedonia in Patients with Primary Biliary Cholangitis: A Cross-Sectional Study
Mehmet Ali Saruhan et al., Journal of Clinical Medicine (15 October 2026)
https://doi.org/10.3390/jcm15207967
- 2.
Clinical, safety, and patient-reported outcomes associated with second-line and later therapies in primary biliary cholangitis: A systematic review
Marco Carbone et al., PubMed Central (14 October 2026)
https://doi.org/10.1097/hc9.0000000000001048
- 3.
Liver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Cross-Sectional Study
Victoria Abadi-Ron et al., Journal of Clinical Medicine (14 October 2026)
https://doi.org/10.3390/jcm15207928
- 4.
Primary biliary cholangitis in Mexico: an emerging reality in the era of new therapies.
García-Juárez I et al., Revista de gastroenterologia de Mexico (English) (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42875336/
- 5.
Free fatty acid remodeling in early-stage primary biliary cholangitis
Magdalena Rogalska et al., Lipids in Health and Disease (13 October 2026)
https://doi.org/10.1186/s12944-026-03093-z
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617 · Recruiting · Phase 3 · Gilead Sciences
Ages 18 and over
https://clinicaltrials.gov/study/NCT06051617
- 2.
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842 · Recruiting · Phase 3 · Ipsen
Ages 18 and over
https://clinicaltrials.gov/study/NCT06016842
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Biliary Cholangitis
Primary Biliary Cholangitis is a chronic autoimmune liver disease that slowly destroys the small bile ducts within the liver, leading to bile accumulation, liver damage, and eventually cirrhosis. It predominantly affects women over 40, with a prevalence of approximately 1 in 1,000 in that group. UDCA and obeticholic acid are the main treatments.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Background and aim: This study assessed depressive symptoms, sleep quality, and anhedonia in patients with primary biliary cholangitis (PBC), compared them with healthy controls (HCs), and explored their associations with UDCA treatment response, established prognostic scores, and liver stiffness measurement (LSM) in patients with PBC. Methods: In this single-center cross-sectional study, 103 patients with PBC and 50 HCs were evaluated using three validated patient-reported outcome (PRO) instruments: the Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), and Snaith–Hamilton Pleasure Scale (SHAPS). PRO measures were compared between patients with PBC and HCs, and associations between PROs and UDCA treatment response, prognostic scores, and LSM were explored in the PBC group. Results: Moderate-to-severe depressive symptoms, poor sleep quality, and anhedonia were observed in 45%, 62%, and 36% of patients with PBC, respectively, compared with 18%, 38%, and 18% of HCs. The age- and sex-adjusted odds ratios (ORs) for PBCvs. HC were 3.889 (95% CI 1.695–8.926), 3.442 (95% CI 1.636–7.238), and 2.678 (95% CI 1.158–6.193), respectively. Younger age was independently associated with poor sleep quality (OR per year 0.946, 95% CI 0.898–0.997; p = 0.039). No statistically significant associations were identified between PROs and UDCA response, prognostic scores, and LSM in patients with PBC. Conclusions: Patients with PBC reported a substantial and interrelated burden of depressive symptoms, poor sleep quality, and anhedonia compared with HCs.
Common Questions
What is Primary Biliary Cholangitis?
Primary Biliary Cholangitis is a chronic autoimmune liver disease that slowly destroys the small bile ducts within the liver, leading to bile accumulation, liver damage, and eventually cirrhosis. It predominantly affects women over 40, with a prevalence of approximately 1 in 1,000 in that group. UDCA and obeticholic acid are the main treatments.
How many clinical trials are available for Primary Biliary Cholangitis?
RareWays currently indexes 139 clinical trials for Primary Biliary Cholangitis, of which 14 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Primary Biliary Cholangitis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Primary Biliary Cholangitis.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.